Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Jevnikar (Le Kremlin-Bicêtre, France), N. Ebstein (Le Kremlin-Bicêtre, France), X. Jais (Le Kremlin-Bicêtre, France), A. Boucly (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France). Efficacy and safety of tadalafil in portopulmonary hypertension. 3050

Member's Comments

No comment yet.

Related content which might interest you: Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Efficacy and safety of bosentan in portopulmonary hypertension according to the severity of liver disease Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Iloprost treatment in portopulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: 563-567 Year: 2006 Experience with inhaled iloprost and bosentan in portopulmonary hypertension Source: Eur Respir J 2007; 30: 1096-1102 Year: 2007 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013